Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease

Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase ad...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Ben Seltzer
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
: galantamine cholinesterase inhibitors Alzheimer's disease
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/ec5eae3b2b564894b57d87d60ff67430
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ec5eae3b2b564894b57d87d60ff67430
record_format dspace
spelling oai:doaj.org-article:ec5eae3b2b564894b57d87d60ff674302021-12-02T03:01:15ZGalantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease1178-1998https://doaj.org/article/ec5eae3b2b564894b57d87d60ff674302009-12-01T00:00:00Zhttps://www.dovepress.com/galantamine-er-for-the-treatment-of-mild-to-moderate-alzheimerrsquos-d-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer’s disease (AD). Except for predicted differences in (Cmax) and tmax, comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.Keywords: galantamine, cholinesterase inhibitors, Alzheimer’s diseaseBen SeltzerDove Medical Pressarticle: galantamine cholinesterase inhibitors Alzheimer's diseaseGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 1-6 (2009)
institution DOAJ
collection DOAJ
language EN
topic : galantamine cholinesterase inhibitors Alzheimer's disease
Geriatrics
RC952-954.6
spellingShingle : galantamine cholinesterase inhibitors Alzheimer's disease
Geriatrics
RC952-954.6
Ben Seltzer
Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
description Ben SeltzerGeriatric Research, Education and Clinical Center, VA Boston Healthcare System, Department of Neurology, Harvard Medical School, Boston, MA, USAAbstract: An extended release form of the cholinesterase inhibitor (ChEI) drug galantamine (galantamine-ER) was developed, chiefly to increase adherence to medication regimes in patients with mild-to-moderate Alzheimer’s disease (AD). Except for predicted differences in (Cmax) and tmax, comparable doses of once daily galantamine-ER and regular, immediate release galantamine, (galantamine-IR), are pharmacologically equivalent. A 24-week randomized, double-blind, placebo-and active-controlled, multicenter phase III trial, which compared galantamine-IR, galantamine-ER and placebo in subjects with mild to moderate AD (mini-mental state examination [MMSE] score range, 10 to 24) showed that both formulations of galantamine were significantly better than placebo in terms of cognition, although not with regard to global change. There was no difference in drug-related adverse events between galantamine-ER and galantamine-IR. Since its release onto the market galantamine-ER has enjoyed wide popularity and a recent surveillance study suggests that it has the highest 1-year persistence rate of all the ChEIs.Keywords: galantamine, cholinesterase inhibitors, Alzheimer’s disease
format article
author Ben Seltzer
author_facet Ben Seltzer
author_sort Ben Seltzer
title Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
title_short Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
title_full Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
title_fullStr Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
title_full_unstemmed Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
title_sort galantamine-er for the treatment of mild-to-moderate alzheimer’s disease
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/ec5eae3b2b564894b57d87d60ff67430
work_keys_str_mv AT benseltzer galantamineerforthetreatmentofmildtomoderatealzheimerrsquosdisease
_version_ 1718402014956748800

Ejemplares similares